HC Wainwright Issues Pessimistic Forecast for CNTX Earnings

Context Therapeutics Inc. (NASDAQ:CNTX) – Equities researchers at HC Wainwright reduced their Q2 2025 earnings per share (EPS) estimates for shares of Context Therapeutics in a research note issued on Thursday, May 8th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($0.05) for the quarter, down from their previous estimate of ($0.04). HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Context Therapeutics’ Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.22) EPS, FY2026 earnings at ($0.34) EPS, FY2027 earnings at ($0.44) EPS, FY2028 earnings at ($0.48) EPS and FY2029 earnings at ($0.32) EPS.

Other equities analysts have also recently issued research reports about the company. William Blair reiterated an “outperform” rating on shares of Context Therapeutics in a report on Tuesday, April 29th. D. Boral Capital reiterated a “buy” rating and issued a $9.00 target price on shares of Context Therapeutics in a report on Thursday, May 8th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Context Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $5.40.

Context Therapeutics Price Performance

NASDAQ CNTX opened at $0.82 on Monday. The stock has a market capitalization of $73.56 million, a PE ratio of -0.90 and a beta of 2.11. The business has a 50 day simple moving average of $0.78 and a two-hundred day simple moving average of $1.10. Context Therapeutics has a 1-year low of $0.55 and a 1-year high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.05) earnings per share for the quarter, meeting the consensus estimate of ($0.05).

Hedge Funds Weigh In On Context Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CNTX. Shay Capital LLC purchased a new position in Context Therapeutics during the 4th quarter valued at $52,000. MPM Bioimpact LLC purchased a new position in Context Therapeutics during the 4th quarter valued at $15,441,000. Millennium Management LLC boosted its holdings in Context Therapeutics by 24.2% during the 4th quarter. Millennium Management LLC now owns 178,718 shares of the company’s stock valued at $188,000 after acquiring an additional 34,835 shares during the period. Citadel Advisors LLC purchased a new position in Context Therapeutics during the 4th quarter valued at $31,000. Finally, Allostery Investments LP purchased a new position in Context Therapeutics during the 4th quarter valued at $998,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.